<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Genomics Inform</journal-id><journal-id journal-id-type="iso-abbrev">Genomics Inform</journal-id><journal-title-group><journal-title>Genomics &#x00026; Informatics</journal-title></journal-title-group><issn pub-type="ppub">1598-866X</issn><issn pub-type="epub">2234-0742</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39891219</article-id><article-id pub-id-type="pmc">PMC11786383</article-id><article-id pub-id-type="publisher-id">35</article-id><article-id pub-id-type="doi">10.1186/s44342-024-00035-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Analyzing COVID-19 progression with Markov multistage models: insights from a Korean cohort</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ndagijimana</surname><given-names>Frank Aimee Rodrigue</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Park</surname><given-names>Taesung</given-names></name><address><email>tspark@stats.snu.ac.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04h9pn542</institution-id><institution-id institution-id-type="GRID">grid.31501.36</institution-id><institution-id institution-id-type="ISNI">0000 0004 0470 5905</institution-id><institution>Interdisciplinary Program in Bioinformatics, Seoul National University, </institution></institution-wrap>Seoul, Republic of Korea </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04h9pn542</institution-id><institution-id institution-id-type="GRID">grid.31501.36</institution-id><institution-id institution-id-type="ISNI">0000 0004 0470 5905</institution-id><institution>Department of Statistics, </institution><institution>Seoul National University, </institution></institution-wrap>Seoul, Republic of Korea </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>2</elocation-id><history><date date-type="received"><day>31</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>30</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Understanding the progression and recovery process of COVID-19 is crucial for guiding public health strategies and developing targeted interventions. This longitudinal cohort study aims to elucidate the dynamics of COVID-19 severity progression and evaluate the impact of underlying health conditions on these transitions, providing critical insights for more effective disease management.</p></sec><sec><title>Methods</title><p id="Par2">Data from 4549 COVID-19 patients admitted to Seoul National University Boramae Medical Center between February 5th, 2020, and October 30th, 2021, were analyzed using a 5-state continuous-time Markov multistate model. The model estimated instantaneous transition rates between different levels of COVID-19 severity, predicted probabilities of state transitions, and determined hazard ratios associated with underlying comorbidities.</p></sec><sec><title>Results</title><p id="Par3">The analysis revealed that most patients stabilized in their initial state, with 72.2% of patients with moderate symptoms remaining moderate. Patients with hypertension had a 67.6% higher risk of progressing from moderate to severe, while those with diabetes had an 89.9% higher risk of deteriorating from severe to critical. Although transition rates to death were low early in hospitalization, these comorbidities significantly increased the likelihood of worsening conditions.</p></sec><sec><title>Conclusion</title><p id="Par4">This study highlights the utility of continuous-time Markov multistate models in assessing COVID-19 severity progression among hospitalized patients. The findings indicate that patients are more likely to recover than to experience worsening conditions. However, hypertension and diabetes significantly increase the risk of severe outcomes, underscoring the importance of managing these conditions in COVID-19 patients.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s44342-024-00035-y.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>COVID-19 progression</kwd><kwd>Markov multistate model</kwd><kwd>Transition intensity</kwd><kwd>Comorbidity</kwd><kwd>Severity state</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003725</institution-id><institution>National Research Foundation of Korea</institution></institution-wrap></funding-source><award-id>2021M3E5E3081425</award-id><award-id>2021M3E5E3081425</award-id><principal-award-recipient><name><surname>Ndagijimana</surname><given-names>Frank Aimee Rodrigue</given-names></name><name><surname>Park</surname><given-names>Taesung</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Korea Genome Organization 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">COVID-19, or coronavirus disease 2019, is a highly contagious illness primarily impacting the respiratory system. It is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an enveloped, single-stranded positive-sense RNA virus classified within the <italic>Betacoronavirus</italic> genus of the <italic>Coronaviridae</italic> family [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. This virus first emerged in December 2019 in Wuhan, the capital of Hubei province in China [<xref ref-type="bibr" rid="CR3">3</xref>]. The spread of this virus worldwide led to unprecedented changes in daily lifestyle that significantly influenced the global economy and led to profound changes in social life and public health [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. SARS-CoV-2 is predominantly transmitted through respiratory secretions, particularly droplets expelled during coughing, sneezing, and talking. Moreover, transmission can occur through personal contact and contaminated surfaces or fomites, especially in settings where non-pharmaceutical interventions (NPIs), including hand hygiene, the proper use of masks, and appropriate social distancing, are not consistently implemented [<xref ref-type="bibr" rid="CR8">8</xref>]. Furthermore, airborne transmission of smaller aerosolized droplets is possible, particularly in enclosed or poorly ventilated environments [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. International air travel has significantly accelerated the spread of the virus, exacerbating its cross-border transmission [<xref ref-type="bibr" rid="CR11">11</xref>]. Consequently, the World Health Organization (WHO) declared COVID-19 a public health emergency of international concern on January 30, 2020 [<xref ref-type="bibr" rid="CR12">12</xref>], and elevated it to a global pandemic on March 11, 2020 [<xref ref-type="bibr" rid="CR13">13</xref>]. As of September 2024, the World Health Organization (WHO) reports more than 776 million confirmed cases and over 7 million deaths globally [<xref ref-type="bibr" rid="CR14">14</xref>]. COVID-19 presents a wide range of clinical manifestations, with symptoms that can vary between patients and fluctuate over time, ranging from mild to severe, while some individuals may remain asymptomatic [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par6">Reflecting the varying clinical manifestations of COVID-19, the World Health Organization (WHO) has established comprehensive guidelines based on clinical symptoms to categorize the severity of COVID-19 infections, facilitating optimal patient management and the efficient allocation of medical resources [<xref ref-type="bibr" rid="CR16">16</xref>]. This classification system categorizes cases of infection into five distinct states: asymptomatic (presymptomatic), mild, moderate, severe, and critical. Asymptomatic individuals test positive for SARS-CoV-2 virus but do not show any symptoms of the infection. Mild cases typically present with symptoms like fever, cough, and loss of taste or smell without respiratory distress. Moderate cases show lower respiratory issues with oxygen saturation (SpO2) at 94% or higher on room air. Severe cases include more serious respiratory problems, such as SpO2 below 94% or a respiratory rate over 30 breaths per minute. Critical cases involve life-threatening conditions like respiratory failure, septic shock, or multiple organ dysfunction. The diverse clinical manifestations of COVID-19 are influenced by demographic factors such as age and sex, along with pre-existing chronic health conditions. Research consistently highlights that older adults and those with chronic illnesses such as hypertension and diabetes are at notably higher risk for adverse disease outcomes including symptom aggravation, admission to the intensive care unit (ICU), and death [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par7">The COVID-19 pandemic has placed an unprecedented burden on global public health, overwhelming healthcare systems, depleting critical medical resources, and leading to substantial morbidity and mortality. In response to these challenges, predictive models, including machine learning algorithms and mathematical simulations, have become crucial tools for guiding clinical decision-making, forecasting disease progression and evaluating the effectiveness of interventions to mitigate the pandemic&#x02019;s impact. Among these tools, the open-source online COVID-19 Community Mortality Risk Prediction (CoCoMoRP) model leverages logistic regression to predict mortality risk in South Korea, providing support to healthcare providers and policymakers [<xref ref-type="bibr" rid="CR20">20</xref>]. Machine learning algorithms, including eXtreme Gradient Boosting, K-Nearest Neighbor, Random Forest, bagged-CART, and LogitBoost algorithms were also employed to predict ICU admission, mortality, and length of stay in hospitalized COVID-19 patients [<xref ref-type="bibr" rid="CR21">21</xref>]. Moreover, deep learning approaches integrating X-ray information and clinical data have been proposed to enhance COVID-19 detection, severity classification, and outcome prediction [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. Other studies have aimed to identify risk factors for COVID-19 and examine their associations with disease outcomes. For example, numerous studies have investigated the association between pre-existing comorbidities and mortality, disease severity in patients diagnosed with COVID-19 [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par8">Although existing studies have significantly enhanced our understanding of COVID-19, the temporal progression of COVID-19 severity remains unclear. Much of the current research focuses on predicting endpoints such as recovery or mortality, with limited attention to dynamic transitions between the severity states. The mechanisms driving these transitions and the role of comorbidities in shaping patients&#x02019; trajectories, remain poorly understood. Therefore, a nuanced understanding of how and when individuals progress from one state of severity to another is crucial for shaping proactive, real-time interventions that address disease progression in its intermediate stages rather than solely forecasting terminal endpoints. To study these transitions comprehensively, several studies have been proposed based on Markov models and multistate models which are essential tools for analyzing stochastic processes involving state transitions. These models are governed by the Markov property, which states that the future state solely depends on the current state of the process. Markov models are simpler and ideal for studying population-level dynamics, such as disease transmission and intervention outcomes. On the other hand, multistate models extend this framework by incorporating multiple interconnected states, enabling detailed analyses of complex systems while still adhering to the Markov property. In the context of COVID-19, these models have been applied to study disease transmission, patient outcomes, and intervention strategies. For example, a study by Noh et al. investigated the phase shifts in SARS-Cov-2 sub-lineages by employing a Markov switching model [<xref ref-type="bibr" rid="CR27">27</xref>]. Another study by Wang and Mustafa applied a data-driven Markov model to evaluate COVID-19 transmission dynamics and interventions [<xref ref-type="bibr" rid="CR28">28</xref>]. Hazard et al. employed multistate models with four states to study the progress of patients admitted to the ICU [<xref ref-type="bibr" rid="CR29">29</xref>]. Al-Zoughool et al. employed a stochastic Continuous-Time Markov Chain (CTMC) model with eight states to simulate the transmission dynamics of SARS-CoV-2 [<xref ref-type="bibr" rid="CR30">30</xref>]. The analysis focused on evaluating various hypothetical lockdown scenarios to determine the optimal timing and duration of lockdown measures that could effectively control new infections and reduce hospitalizations.</p><p id="Par9">While these Markov multistate models have been applied to several COVID-19 studies, none have been applied to the Korean population. Since it is well known that the progress of COVID-19 would differ depending on race and national pandemic prevention policies [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>], it would be important to study the progression of COVID-19 in the South Korean population. Thus, the present study employs Markov multistate models to analyze the progression of disease severity within a longitudinal cohort of hospitalized COVID-19 patients from a Korean hospital. In particular, we employed a continuous-time Markov multistate model to analyze a longitudinal dataset of COVID-19 patients hospitalized at Seoul National University (SNU) Boramae Medical Center in Seoul, South Korea. The primary aim was to investigate the patterns of disease progression and recovery over time. The model facilitated the estimation of transition intensities, computation of transition probabilities, and determination of mean sojourn times. Furthermore, given that diabetes and hypertension are widely recognized as key contributors to adverse COVID-19 outcomes [<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>], this study also aimed to examine how these conditions, as potential covariates, influence the transitions of disease severity. The findings of this study are expected to inform targeted interventions, optimize resource allocation, and facilitate timely responses to COVID-19, thereby contributing to improved patient outcomes. To the best of our knowledge, this is the first study to employ continuous-time Markov multistate models to investigate the progression of COVID-19 severity in South Korea.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Data acquisition and preprocessing</title><p id="Par10">This study collected data from 4587 COVID-19 patients admitted at Seoul National University (SNU) Boramae Medical Center from February 5, 2020, to October 30, 2021. The demographic and clinical information of the patients were recorded upon admission, and patients were subjected to daily monitoring of disease severity in accordance with the guidelines established by the World Health Organization (WHO) [<xref ref-type="bibr" rid="CR16">16</xref>]. The severity of illness was classified into five states based on clinical manifestations: mild (State 1), moderate (State 2), severe (State 3), critical (State 4), or death (State 5), as outlined in Supplementary Table&#x000a0;S1. The current study defined a shift in severity state as a state transition. The preprocessing step involved the exclusion of 38 patients with incomplete clinical records, resulting in a final dataset of 4549 patients.</p></sec></sec><sec id="Sec4"><title>Markov multistate analysis</title><sec id="Sec5"><title>Multistate model framework</title><p id="Par11">In this study, a continuous-time first-order Markov multistate model was employed to study the transitions between different states of severity of COVID-19, as illustrated in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. In the proposed model, a patient in State 1 may either remain in this state, progress to State 2 or die. An individual in State 2 can either remain in this state, recover to State 1, or advance to either State 3 or State 5. A patient in State 3 may recover to State 2, deteriorate to State 4, or die. Additionally, patients in State 4 may either recover to State 3 or experience death. Once a patient transitions into State 5, no further transitions are permissible, thereby designating this state as the absorbing state within the model.<fig id="Fig1"><label>Fig. 1</label><caption><p>Proposed 5-state model for examining disease progression among COVID-19 patients, SNU Boramae Medical Center</p></caption><graphic xlink:href="44342_2024_35_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec6"><title>Estimation of transition intensities</title><p id="Par12">Multistate models are governed by transition intensity functions that characterize the instantaneous risk of moving from one state to another. In the context of a continuous-time Markov model, the transition intensity from state <italic>i to</italic> state <italic>j</italic>, denoted by <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\uplambda }_{\mathit{ij}}(t)$$\end{document}</tex-math><mml:math id="M2"><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#x003bb;</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq1.gif"/></alternatives></inline-formula>, represents the instantaneous&#x000a0;rate at which patients in state <italic>i</italic> transition to state <italic>j</italic> within a time interval <inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta t$$\end{document}</tex-math><mml:math id="M4"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq2.gif"/></alternatives></inline-formula> given that a patient is in state <italic>i</italic> at time <inline-formula id="IEq3"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$t$$\end{document}</tex-math><mml:math id="M6"><mml:mi>t</mml:mi></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq3.gif"/></alternatives></inline-formula>. This is mathematically expressed as:<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\uplambda }_{\mathit{ij}}(t)=\underset{\Delta t\to 0}{\text{lim}}\frac{P\left(X\left(t+\Delta t\right)=j \right| X\left(t\right)=i)}{\Delta t}$$\end{document}</tex-math><mml:math id="M8" display="block"><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#x003bb;</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:munder><mml:mtext>lim</mml:mtext><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">&#x02192;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:munder><mml:mfrac><mml:mrow><mml:mi>P</mml:mi><mml:mfenced close="|" open="("><mml:mi>X</mml:mi><mml:mfenced close=")" open="("><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>t</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:mi>j</mml:mi></mml:mfenced><mml:mi>X</mml:mi><mml:mfenced close=")" open="("><mml:mi>t</mml:mi></mml:mfenced><mml:mrow><mml:mo>=</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="44342_2024_35_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq4"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\uplambda }_{\mathit{ij}}(t)$$\end{document}</tex-math><mml:math id="M10"><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#x003bb;</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq4.gif"/></alternatives></inline-formula> is the transition intensity from state <italic>i</italic> to state <italic>j</italic>, and <inline-formula id="IEq5"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$P\left(X\left(t+\Delta t\right)=j \right| X\left(t\right)=i)$$\end{document}</tex-math><mml:math id="M12"><mml:mrow><mml:mi>P</mml:mi><mml:mfenced close="|" open="("><mml:mi>X</mml:mi><mml:mfenced close=")" open="("><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>t</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:mi>j</mml:mi></mml:mfenced><mml:mi>X</mml:mi><mml:mfenced close=")" open="("><mml:mi>t</mml:mi></mml:mfenced><mml:mrow><mml:mo>=</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq5.gif"/></alternatives></inline-formula> denotes the probability of transition from state <inline-formula id="IEq6"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="M14"><mml:mi>i</mml:mi></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq6.gif"/></alternatives></inline-formula> to state <inline-formula id="IEq7"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$j$$\end{document}</tex-math><mml:math id="M16"><mml:mi>j</mml:mi></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq7.gif"/></alternatives></inline-formula> over the time interval <inline-formula id="IEq8"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta t$$\end{document}</tex-math><mml:math id="M18"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq8.gif"/></alternatives></inline-formula>. The collection of transition intensities constitutes the transition intensity matrix <inline-formula id="IEq9"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Q$$\end{document}</tex-math><mml:math id="M20"><mml:mi>Q</mml:mi></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq9.gif"/></alternatives></inline-formula>, which encompasses all possible transition rates among the various states.</p><p id="Par13">Transition intensities between states were estimated by maximizing the likelihood function based on each patient&#x02019;s observed transitions over time. For a patient in state <italic>i</italic>, the likelihood of transitioning to state <italic>j</italic> during the time interval <inline-formula id="IEq10"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta t={[\text{t}}_{i-1,}{\text{t}}_{i}]$$\end{document}</tex-math><mml:math id="M22"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mtext>t</mml:mtext></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:msub><mml:msub><mml:mtext>t</mml:mtext><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq10.gif"/></alternatives></inline-formula> is represented by the transition probability <inline-formula id="IEq11"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$P(X({t}_{i})=j\mid X({t}_{i-1})=i,Q)$$\end{document}</tex-math><mml:math id="M24"><mml:mrow><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>X</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>j</mml:mi><mml:mo>&#x02223;</mml:mo><mml:mi>X</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>Q</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq11.gif"/></alternatives></inline-formula> where <inline-formula id="IEq12"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Q$$\end{document}</tex-math><mml:math id="M26"><mml:mi>Q</mml:mi></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq12.gif"/></alternatives></inline-formula> denotes the matrix of transition intensities. The overall likelihood for a dataset with&#x000a0;N&#x000a0;patients is expressed as:<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\prod_{i=1}^{N}\prod_{{[\text{t}}_{i-1,}{\text{t}}_{i}]}P(X({t}_{i})=j\mid X({t}_{i-1})=i,Q)$$\end{document}</tex-math><mml:math id="M28" display="block"><mml:mrow><mml:munderover><mml:mo>&#x0220f;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:munder><mml:mo>&#x0220f;</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mtext>t</mml:mtext></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:msub><mml:msub><mml:mtext>t</mml:mtext><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:munder><mml:mi>P</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>X</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>j</mml:mi><mml:mo>&#x02223;</mml:mo><mml:mi>X</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>Q</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><graphic xlink:href="44342_2024_35_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula></p></sec><sec id="Sec7"><title>Transition probability matrix and mean sojourn times</title><p id="Par14">The transition probability matrix, <inline-formula id="IEq13"><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$P\left(t\right)$$\end{document}</tex-math><mml:math id="M30"><mml:mrow><mml:mi>P</mml:mi><mml:mfenced close=")" open="("><mml:mi>t</mml:mi></mml:mfenced></mml:mrow></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq13.gif"/></alternatives></inline-formula> is a matrix that provides the probabilities of being in a state <inline-formula id="IEq14"><alternatives><tex-math id="M31">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$j$$\end{document}</tex-math><mml:math id="M32"><mml:mi>j</mml:mi></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq14.gif"/></alternatives></inline-formula> at time <inline-formula id="IEq15"><alternatives><tex-math id="M33">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$t$$\end{document}</tex-math><mml:math id="M34"><mml:mi>t</mml:mi></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq15.gif"/></alternatives></inline-formula> after being in state <inline-formula id="IEq16"><alternatives><tex-math id="M35">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="M36"><mml:mi>i</mml:mi></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq16.gif"/></alternatives></inline-formula> at time <inline-formula id="IEq17"><alternatives><tex-math id="M37">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$t-1$$\end{document}</tex-math><mml:math id="M38"><mml:mrow><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq17.gif"/></alternatives></inline-formula>. Each element <inline-formula id="IEq18"><alternatives><tex-math id="M39">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${P}_{ij}(t)$$\end{document}</tex-math><mml:math id="M40"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq18.gif"/></alternatives></inline-formula> of the matrix represents the probability that a patient in state <inline-formula id="IEq19"><alternatives><tex-math id="M41">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="M42"><mml:mi>i</mml:mi></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq19.gif"/></alternatives></inline-formula> at time 0 will be in state <inline-formula id="IEq20"><alternatives><tex-math id="M43">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$j$$\end{document}</tex-math><mml:math id="M44"><mml:mi>j</mml:mi></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq20.gif"/></alternatives></inline-formula> after time <inline-formula id="IEq21"><alternatives><tex-math id="M45">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$t$$\end{document}</tex-math><mml:math id="M46"><mml:mi>t</mml:mi></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq21.gif"/></alternatives></inline-formula>. The transition probability matrix is obtained by taking the matrix exponential of the transition intensity matrix, expressed as the following:<disp-formula id="Equ3"><label>3</label><alternatives><tex-math id="M47">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$P\left(t\right)=\text{Exp}\left(tQ\right)$$\end{document}</tex-math><mml:math id="M48" display="block"><mml:mrow><mml:mi>P</mml:mi><mml:mfenced close=")" open="("><mml:mi>t</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:mtext>Exp</mml:mtext><mml:mfenced close=")" open="("><mml:mi>t</mml:mi><mml:mi>Q</mml:mi></mml:mfenced></mml:mrow></mml:math><graphic xlink:href="44342_2024_35_Article_Equ3.gif" position="anchor"/></alternatives></disp-formula></p><p id="Par15">The mean sojourn times indicate the average time a patient is expected to remain in each state before transitioning to another. For any state <inline-formula id="IEq22"><alternatives><tex-math id="M49">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="M50"><mml:mi>i</mml:mi></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq22.gif"/></alternatives></inline-formula>, the mean sojourn time, denoted as<inline-formula id="IEq23"><alternatives><tex-math id="M51">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\tau }_{i}$$\end{document}</tex-math><mml:math id="M52"><mml:msub><mml:mi>&#x003c4;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq23.gif"/></alternatives></inline-formula>, is calculated as the inverse of the total transition rate out of that state. This is expressed mathematically as the following:<disp-formula id="Equ4"><label>4</label><alternatives><tex-math id="M53">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\tau }_{i}=\frac{1}{\sum_{j\ne i}{\lambda }_{ij}}$$\end{document}</tex-math><mml:math id="M54" display="block"><mml:mrow><mml:msub><mml:mi>&#x003c4;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>&#x02260;</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xlink:href="44342_2024_35_Article_Equ4.gif" position="anchor"/></alternatives></disp-formula></p></sec><sec id="Sec8"><title>Incorporating comorbidities in the model</title><p id="Par16">Patient-specific covariates, diabetes, and hypertension were incorporated into the model to examine the impact of these comorbidities on state transitions. These covariates were chosen based on literature-based evidence of their association with adverse outcomes of COVID-19, including high severity and mortality. Numerous studies have consistently identified diabetes and hypertension as critical risk factors for adverse outcomes of the infection. For example, a study examining chronic diseases in Mexican COVID-19 patients demonstrated that both diabetes and hypertension significantly increased case-fatality rates and contributed to higher disease severity levels among hospitalized individuals [<xref ref-type="bibr" rid="CR33">33</xref>]. Another study assessing risk factors for COVID-19 mortality identified hypertension and diabetes, alongside age and geographic region, as primary determinants of severe outcomes in COVID-19 [<xref ref-type="bibr" rid="CR34">34</xref>]. Furthermore, a systematic review and meta-analysis of risk factors for COVID-19 severity and mortality confirmed that chronic conditions, including diabetes and hypertension, significantly increased the risk of severe outcomes, alongside advanced age and cardiovascular diseases [<xref ref-type="bibr" rid="CR35">35</xref>]. Grounded in well-documented evidence, we incorporated diabetes and hypertension as covariates to critically evaluate their role in driving state transitions and determining the progression of COVID-19 disease.</p><p id="Par17">The transition intensities <inline-formula id="IEq24"><alternatives><tex-math id="M55">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{ij}$$\end{document}</tex-math><mml:math id="M56"><mml:msub><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq24.gif"/></alternatives></inline-formula> between states are modeled as a function of these covariates, using a proportional hazards framework. The adjusted transition intensity is expressed as the following:<disp-formula id="Equa"><alternatives><tex-math id="M57">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{ij}\left(t|Z\right)= {\lambda }_{ij}^{0}\left(\text{t}\right)\text{ exp}({\beta }_{ij}^{T}Z)$$\end{document}</tex-math><mml:math id="M58" display="block"><mml:mrow><mml:msub><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mfenced close=")" open="("><mml:mi>t</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mi>Z</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:msubsup><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup><mml:mfenced close=")" open="("><mml:mtext>t</mml:mtext></mml:mfenced><mml:mspace width="0.333333em"/><mml:mtext>exp</mml:mtext><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow><mml:mi>T</mml:mi></mml:msubsup><mml:mi>Z</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><graphic xlink:href="44342_2024_35_Article_Equa.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq25"><alternatives><tex-math id="M59">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\lambda }_{ij}^{0}\left(\text{t}\right)$$\end{document}</tex-math><mml:math id="M60"><mml:mrow><mml:msubsup><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup><mml:mfenced close=")" open="("><mml:mtext>t</mml:mtext></mml:mfenced></mml:mrow></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq25.gif"/></alternatives></inline-formula> indicates the baseline transition intensity from state <inline-formula id="IEq26"><alternatives><tex-math id="M61">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="M62"><mml:mi>i</mml:mi></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq26.gif"/></alternatives></inline-formula> to state <inline-formula id="IEq27"><alternatives><tex-math id="M63">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$j$$\end{document}</tex-math><mml:math id="M64"><mml:mi>j</mml:mi></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq27.gif"/></alternatives></inline-formula>, <inline-formula id="IEq28"><alternatives><tex-math id="M65">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\beta }_{ij}$$\end{document}</tex-math><mml:math id="M66"><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq28.gif"/></alternatives></inline-formula> is a vector of coefficients representing the effects of the covariates and <inline-formula id="IEq29"><alternatives><tex-math id="M67">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Z$$\end{document}</tex-math><mml:math id="M68"><mml:mi>Z</mml:mi></mml:math><inline-graphic xlink:href="44342_2024_35_Article_IEq29.gif"/></alternatives></inline-formula> is a vector of covariates.</p><p id="Par18">All analyses were conducted utilizing the msm package [<xref ref-type="bibr" rid="CR36">36</xref>], which is available in the free software R (version 4.3.3; <ext-link ext-link-type="uri" xlink:href="https://www.r-project.org">https://www.r-project.org</ext-link>).</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Data characteristics</title><p id="Par19">The data preprocessing yielded a dataset of 4549 patients prepared for analysis as illustrated in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>. At the time of admission, 541 patients (11.89%) presented with mild symptoms, while 3390 patients (74.52%) exhibited moderate symptoms, and 615 patients (13.52%) were classified as having severe symptoms. Additionally, 3 patients (0.07%) were categorized as having critical symptoms of COVID-19. The ages of the participants ranged from 18 to 101&#x000a0;years, with a median age of 53 (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Regarding gender distribution, 2,448 patients (53.81%) were female, compared to 2,105 patients (46.19%) who were male, indicating a marginally higher representation of females. Among the recorded comorbidities, hypertension was the most prevalent, affecting 27.59% of patients, followed by diabetes at 14.9% (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Other concurrent diseases included dementia (5.34%), malignant neoplasms (4.37%), heart failure (3.72%), asthma (2.02%), chronic liver disease (1.38%), chronic cardiac disease (1.32%), chronic neurological disorders (1.06%), chronic kidney disease (0.97%), chronic obstructive pulmonary disease (0.37%), and chronic hematologic disease (0.35%).<fig id="Fig2"><label>Fig. 2</label><caption><p>Pre-processing and composition of SNU Borame Hospital COVID-19 cohort</p></caption><graphic xlink:href="44342_2024_35_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Demographic and clinical characteristics of Borame Hospital COVID-19 cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics</th><th align="left" colspan="5">Values</th></tr></thead><tbody><tr><td align="left" colspan="6">Demographics</td></tr><tr><td align="left"/><td align="left">Min</td><td align="left">Mean (SD)</td><td align="left" colspan="2">Median</td><td align="left">Max</td></tr><tr><td align="left">&#x02003;Age (years)</td><td align="left">18.00</td><td align="left">52.97 (17.57)</td><td align="left" colspan="2">53.00</td><td align="left">101</td></tr><tr><td align="left">&#x02003;Body mass index (Kg/m<sup>2</sup>)</td><td align="left">10.72</td><td align="left">24.30 (4.15)</td><td align="left" colspan="2">24.00</td><td align="left">59.52</td></tr><tr><td align="left" rowspan="2">&#x02003;Gender</td><td align="left" colspan="2">Male, <italic>n</italic> (%)</td><td align="left" colspan="3">2101 (46.19)</td></tr><tr><td align="left" colspan="2">Female, <italic>n</italic> (%)</td><td align="left" colspan="3">2448 (53.81)</td></tr><tr><td align="left" rowspan="2">&#x02003;Current smoker</td><td align="left" colspan="2">Yes, <italic>n</italic> (%)</td><td align="left" colspan="3">510 (11.21)</td></tr><tr><td align="left" colspan="2">No, <italic>n</italic> (%)</td><td align="left" colspan="3">4039 (88.79)</td></tr><tr><td align="left" colspan="6">Vital signs on admission</td></tr><tr><td align="left"/><td align="left">Min</td><td align="left">Mean (SD)</td><td align="left" colspan="2">Median</td><td align="left">Max</td></tr><tr><td align="left">&#x02003;Heart rate (beats/min)</td><td align="left">42.00</td><td align="left">89.68 (14.85)</td><td align="left" colspan="2">89.00</td><td align="left">143.00</td></tr><tr><td align="left">&#x02003;Systolic blood pressure (mmHg)</td><td align="left">66.00</td><td align="left">131.18 (18.96)</td><td align="left" colspan="2">130.00</td><td align="left">222.00</td></tr><tr><td align="left">&#x02003;Body temperature (<sup>o</sup>C)</td><td align="left">33.80</td><td align="left">37.04 (0.80)</td><td align="left" colspan="2">36.9</td><td align="left">40.40</td></tr><tr><td align="left">&#x02003;Respiration rate (breaths/min)</td><td align="left">14.00</td><td align="left">19.66&#x000a0;(3.27)</td><td align="left" colspan="2">20.00</td><td align="left">98.00</td></tr><tr><td align="left" colspan="6">Comorbidities</td></tr><tr><td align="left"/><td align="left" colspan="3">Yes, <italic>n</italic> (%)</td><td align="left" colspan="2">No, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x02003;Hypertension</td><td align="left" colspan="3">1255 (27.59)</td><td align="left" colspan="2">3294 (72.41)</td></tr><tr><td align="left">&#x02003;Diabetes mellitus</td><td align="left" colspan="3">678 (14.90)</td><td align="left" colspan="2">3871 (85.10)</td></tr><tr><td align="left">&#x02003;Dementia</td><td align="left" colspan="3">243 (5.34)</td><td align="left" colspan="2">4306 (94.66)</td></tr><tr><td align="left">&#x02003;Malignancy</td><td align="left" colspan="3">199 (4.37)</td><td align="left" colspan="2">4350&#x000a0;(95.63)</td></tr><tr><td align="left">&#x02003;Heart failure</td><td align="left" colspan="3">169 (3.72)</td><td align="left" colspan="2">4380 (96.28)</td></tr><tr><td align="left">&#x02003;Asthma</td><td align="left" colspan="3">92 (2.02)</td><td align="left" colspan="2">4457 (97.98)</td></tr><tr><td align="left">&#x02003;Chronic liver disease</td><td align="left" colspan="3">63 (1.38)</td><td align="left" colspan="2">4486 (98.62)</td></tr><tr><td align="left">&#x02003;Chronic cardiac disease</td><td align="left" colspan="3">60 (1.32)</td><td align="left" colspan="2">4489 (98.68)</td></tr><tr><td align="left">&#x02003;Chronic neurological disorder</td><td align="left" colspan="3">48 (1.06)</td><td align="left" colspan="2">4501 (98.94)</td></tr><tr><td align="left">&#x02003;Chronic kidney disease</td><td align="left" colspan="3">44 (0.97)</td><td align="left" colspan="2">4505 (99.03)</td></tr><tr><td align="left">&#x02003;Chronic obstructive pulmonary disease</td><td align="left" colspan="3">17 (0.37)</td><td align="left" colspan="2">4532 (99.63)</td></tr><tr><td align="left">&#x02003;Chronic hematological disease</td><td align="left" colspan="3">16 (0.35)</td><td align="left" colspan="2">4533 (99.65)</td></tr><tr><td align="left" colspan="6">Symptoms on admission</td></tr><tr><td align="left"/><td align="left" colspan="3"><p>Yes</p><p><italic>n</italic> (%)</p></td><td align="left" colspan="2"><p>No</p><p><italic>n</italic> (%)</p></td></tr><tr><td align="left">&#x02003;Cough</td><td align="left" colspan="3">2330 (51.22)</td><td align="left" colspan="2">2219 (48.78)</td></tr><tr><td align="left">&#x02003;Sputum</td><td align="left" colspan="3">1471 (32.34)</td><td align="left" colspan="2">3078 (67.66)</td></tr><tr><td align="left">&#x02003;Headache</td><td align="left" colspan="3">993 (21.83)</td><td align="left" colspan="2">3556 (78.17)</td></tr><tr><td align="left">&#x02003;Sore throat</td><td align="left" colspan="3">914 (20.09)</td><td align="left" colspan="2">3635 (79.91)</td></tr><tr><td align="left">&#x02003;Myalgia</td><td align="left" colspan="3">872 (19.17)</td><td align="left" colspan="2">3677 (80.83)</td></tr><tr><td align="left">&#x02003;Vomiting/nausea</td><td align="left" colspan="3">398 (8.75)</td><td align="left" colspan="2">4151 (91.25)</td></tr><tr><td align="left">&#x02003;Diarrhea</td><td align="left" colspan="3">305 (6.70)</td><td align="left" colspan="2">4244 (93.30)</td></tr><tr><td align="left">&#x02003;Fatigue/malaise</td><td align="left" colspan="3">292 (6.42)</td><td align="left" colspan="2">4257 (93.58)</td></tr><tr><td align="left">&#x02003;Rhinorrhea</td><td align="left" colspan="3">241 (5.30)</td><td align="left" colspan="2">4308 (94.70)</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec11"><title>Markov multistate analysis</title><sec id="Sec12"><title>Frequencies of state transitions</title><p id="Par20">The frequencies of transitions between consecutive observed states during the first 2&#x000a0;weeks of hospitalization are presented in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Most transitions involve patients remaining in the same state. The most frequent transitions were patients remaining in State 2 (21,899 cases), followed by those remaining in State 1 (3506 cases) and State 3 (2901 cases). Transitions to lower states of severity outnumbered transitions to relatively more severe states. Specifically, 837 patients improved from State 2 to State 1, compared to 717 who worsened to State 3. Transitions directly to State 5 were rare. Notably, only four deaths were recorded from State 3, and one death was recorded from State 4.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Distribution of consecutive observed states among COVID-19 patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Prior state</th><th align="left" colspan="5">Next state</th></tr><tr><th align="left">State 1</th><th align="left">State 2</th><th align="left">State 3</th><th align="left">State 4</th><th align="left">State 5</th></tr></thead><tbody><tr><td align="left">State 1</td><td align="left">3506</td><td align="left">491</td><td align="left">127</td><td align="left">0</td><td align="left">0</td></tr><tr><td align="left">State 2</td><td align="left">837</td><td align="left">21,899</td><td align="left">717</td><td align="left">8</td><td align="left">1</td></tr><tr><td align="left">State 3</td><td align="left">139</td><td align="left">460</td><td align="left">2901</td><td align="left">40</td><td align="left">4</td></tr><tr><td align="left">State 4</td><td align="left">0</td><td align="left">8</td><td align="left">17</td><td align="left">100</td><td align="left">1</td></tr><tr><td align="left">State 5</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec13"><title>Estimated transition intensities</title><p id="Par21">Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> presents the primary results from our multistate analyses. For patients in State 1, the transition rate to State 2, <italic>&#x003bb;</italic><sub><italic>12</italic></sub> is 0.168, identical to the rate of remaining in the same state (&#x003bb;<sub><italic>11</italic></sub>&#x02009;=&#x02009;0.168). Individuals in State 2 are 1.13 times more likely to improve to a mild state (&#x003bb;<sub><italic>21</italic></sub>&#x02009;=&#x02009;0.046) than to aggravate to a severe state (&#x003bb;<sub><italic>23</italic></sub>&#x02009;=&#x02009;0.041), indicating a slight tendency toward improvement. Once in State 3, patients have a 13 times higher recovery rate to State 2 (&#x003bb;<sub><italic>32</italic></sub>&#x02009;=&#x02009;0.195) compared to progression to State 4 (&#x003bb;<sub><italic>34</italic></sub>&#x02009;=&#x02009;0.015), suggesting a greater likelihood of recovery even in severe conditions. Transition rates to State 5 were very low. For instance, the estimated transition rate from State 4 to 5 (<italic>&#x003bb;</italic><sub><italic>45</italic></sub>) was 0.011, while that from State 3 to 5 (&#x003bb;<sub><italic>35</italic></sub>) was 0.001.
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Estimated transition intensity matrix of the multistate model among COVID-19 patients in the Boramae Hospital cohort study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Prior state</th><th align="left" colspan="5">Next state</th></tr><tr><th align="left">State 1</th><th align="left">State 2</th><th align="left">State 3</th><th align="left">State 4</th><th align="left">State 5</th></tr></thead><tbody><tr><td align="left">State 1</td><td align="left"><p>&#x02009;&#x02212;&#x02009;0.1681</p><p>(&#x02212;&#x02009;0.182,&#x02009;&#x02212;&#x02009;0.155)</p></td><td align="left"><p>0.1681</p><p>(0.155, 0.182)</p></td><td align="left">0</td><td align="left">0</td><td align="left"><p>2.649e<sup>&#x02212;09</sup></p><p>(2.343e<sup>&#x02212;293</sup>, 2.993e<sup>+275</sup>)</p></td></tr><tr><td align="left">State 2</td><td align="left"><p>0.046</p><p>(0.044, 0.0494)</p></td><td align="left"><p>&#x02009;&#x02212;&#x02009;0.087</p><p>(&#x02212;&#x02009;0.091,&#x02009;&#x02212;&#x02009;0.083)</p></td><td align="left"><p>0.041</p><p>(0.038, 0.044)</p></td><td align="left">0</td><td align="left"><p>2.194e-07</p><p>(5.359e<sup>&#x02212;40</sup>, 8.986e<sup>25</sup>)</p></td></tr><tr><td align="left">State 3</td><td align="left">0</td><td align="left"><p>0.195</p><p>(0.179, 0.211)</p></td><td align="left"><p>&#x02009;&#x02212;&#x02009;0.211</p><p>(&#x02212;&#x02009;0.228,&#x02009;&#x02212;&#x02009;0.196)</p></td><td align="left"><p>0.015</p><p>(0.011, 0.019)</p></td><td align="left"><p>0.001</p><p>(4.514e<sup>&#x02212;04</sup>, 3.423e-<sup>03</sup>)</p></td></tr><tr><td align="left">State 4</td><td align="left">0</td><td align="left">0</td><td align="left"><p>0.226</p><p>(0.015, 0.334)</p></td><td align="left"><p>&#x02009;&#x02212;&#x02009;0.237</p><p>(&#x02212;&#x02009;0.348,&#x02009;&#x02212;&#x02009;0.161)</p></td><td align="left"><p>0.011</p><p>(0.002, 0.082)</p></td></tr><tr><td align="left">State 5</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec14"><title>Estimated transition probabilities and mean sojourn times</title><p id="Par22">Using the estimated transition intensities, we calculated the probabilities of moving to different states after 7, 14, and 30&#x000a0;days following hospital admission as illustrated in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>. After 1&#x000a0;week, patients in State 1 were most likely to transition to State 2, with a probability of 0.551 (55.1%). Those in State 2 had a higher likelihood (72.2%) of remaining in the same state, with chances of improving to State 1 (15.2%) or worsening to State 3 at 12.1%. Patients in State 3 tended to stay in that state (31.3%) or improve to State 2 (57.4%).
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Estimated transition probabilities within 7, 14 and 30&#x000a0;days after hospitalization</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Time and state</th><th align="left" colspan="5">Estimated transition probability</th></tr><tr><th align="left">State 1</th><th align="left">State 2</th><th align="left">State 3</th><th align="left">State 4</th><th align="left">State 5</th></tr></thead><tbody><tr><td align="left" colspan="6">7&#x000a0;days</td></tr><tr><td align="left">&#x02003;State 1</td><td align="left">0.385</td><td align="left">0.551</td><td align="left">0.062</td><td align="left">0.002</td><td align="left">3e<sup>&#x02212;04</sup></td></tr><tr><td align="left">&#x02003;State 2</td><td align="left">0.152</td><td align="left">0.722</td><td align="left">0.121</td><td align="left">0.005</td><td align="left">0.001</td></tr><tr><td align="left">&#x02003;State 3</td><td align="left">0.082</td><td align="left">0.574</td><td align="left">0.313</td><td align="left">0.025</td><td align="left">0.006</td></tr><tr><td align="left">&#x02003;State 4</td><td align="left">0.036</td><td align="left">0.345</td><td align="left">0.369</td><td align="left">0.208</td><td align="left">0.041</td></tr><tr><td align="left">&#x02003;State 5</td><td align="left">0.000</td><td align="left">0.000</td><td align="left">0.000</td><td align="left">0.000</td><td align="left">1.000</td></tr><tr><td align="left" colspan="6">14&#x000a0;days</td></tr><tr><td align="left">&#x02003;State 1</td><td align="left">0.237</td><td align="left">0.646</td><td align="left">0.111</td><td align="left">0.005</td><td align="left">0.001</td></tr><tr><td align="left">&#x02003;State 2</td><td align="left">0.178</td><td align="left">0.675</td><td align="left">0.136</td><td align="left">0.008</td><td align="left">0.003</td></tr><tr><td align="left">&#x02003;State 3</td><td align="left">0.145</td><td align="left">0.648</td><td align="left">0.182</td><td align="left">0.016</td><td align="left">0.010</td></tr><tr><td align="left">&#x02003;State 4</td><td align="left">0.104</td><td align="left">0.553</td><td align="left">0.236</td><td align="left">0.054</td><td align="left">0.053</td></tr><tr><td align="left">&#x02003;State 5</td><td align="left">0.000</td><td align="left">0.000</td><td align="left">0.000</td><td align="left">0.000</td><td align="left">1.000</td></tr><tr><td align="left" colspan="6">30&#x000a0;days</td></tr><tr><td align="left">&#x02003;State 1</td><td align="left">0.186</td><td align="left">0.664</td><td align="left">0.136</td><td align="left">0.008</td><td align="left">0.005</td></tr><tr><td align="left">&#x02003;State 2</td><td align="left">0.183</td><td align="left">0.663</td><td align="left">0.138</td><td align="left">0.009</td><td align="left">0.007</td></tr><tr><td align="left">&#x02003;State 3</td><td align="left">0.179</td><td align="left">0.657</td><td align="left">0.140</td><td align="left">0.009</td><td align="left">0.015</td></tr><tr><td align="left">&#x02003;State 4</td><td align="left">0.166</td><td align="left">0.625</td><td align="left">0.139</td><td align="left">0.011</td><td align="left">0.060</td></tr><tr><td align="left">&#x02003;State 5</td><td align="left">0.000</td><td align="left">0.000</td><td align="left">0.000</td><td align="left">0.000</td><td align="left">1.000</td></tr></tbody></table></table-wrap></p><p id="Par23">By extending the observation period to 2&#x000a0;weeks, the probabilities indicated a strong tendency of patients initially in State 1 to transition to State 2 (64.6%). Those in State 2 mostly stabilized (67.5%), with slightly increased chances of transitioning to State 3 (13.6%) or back to State 1 (17.8%) compared to the first week. Patients admitted in State 3 tended to recover to State 2 (64.8%), while those in State 4 (critical state) showed equal probabilities of either transitioning to State 3 (23.6%) or remaining in State 4 (23.6%).</p><p id="Par24">After about a month, the data demonstrated a consolidation trend for patients initially in State 1 and State 2, with a notable shift towards State 2. The probability of patients initially in State 1 transitioning to State 2 was 66.4%, while for those initially in State 2, it was 66.3%. Patients in State 3 tended to stabilize in State 2 (65.7%), whereas those in State 4 showed an increased probability of transitioning to State 5 (death) at 6.0%.</p><p id="Par25">Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref> demonstrates the mean sojourn times across the non-absorbing states. The estimated mean sojourn times illustrate that moderate symptoms persist longer, with patients remaining in the moderate state for around 11.45&#x000a0;days on average. Relative to this state, the mean sojourn time is shorter in State 4, estimated at 4.225&#x000a0;days, and in State 1, averaging 5.948&#x000a0;days.
<table-wrap id="Tab5"><label>Table 5</label><caption><p>Estimated mean sojourn times of non-absorbing states</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Estimates</th><th align="left">SE</th><th align="left">L</th><th align="left">U</th></tr></thead><tbody><tr><td align="left">State 1</td><td align="left">5.948</td><td align="left">0.240</td><td align="left">5.495</td><td align="left">6.438</td></tr><tr><td align="left">State 2</td><td align="left">11.449</td><td align="left">0.271</td><td align="left">10.931</td><td align="left">11.992</td></tr><tr><td align="left">State 3</td><td align="left">4.738</td><td align="left">0.186</td><td align="left">4.388</td><td align="left">5.116</td></tr><tr><td align="left">State 4</td><td align="left">4.225</td><td align="left">0.832</td><td align="left">2.873</td><td align="left">6.214</td></tr></tbody></table></table-wrap></p><p id="Par26">Estimating transition probabilities and mean sojourn times reveals insights into the progression of COVID-19. After 1&#x000a0;week, patients with mild symptoms were more likely to progress to a moderate state, while those in moderate states tended to remain stable. A consolidation pattern emerged over 2 to 4&#x000a0;weeks, particularly among those initially presenting with mild or moderate symptoms, with a significant shift toward moderate conditions. However, for patients in severe or critical states, the probability of death increased notably over time, highlighting the urgent need for close monitoring and timely intervention in these high-risk groups.</p></sec><sec id="Sec15"><title>Effect of comorbidities on transitions</title><p id="Par27">The results presented in Table&#x000a0;<xref rid="Tab6" ref-type="table">6</xref> highlight the impact of comorbidities, specifically hypertension and diabetes, on the severity and progression of COVID-19. For individuals with hypertension, the hazard ratio for the transition from State 2 to State 3 was 1.676 (95% CI 1.445&#x02013;1.944), indicating a 67.6% increased likelihood of aggravating from moderate to severe symptoms compared to those without hypertension. In the case of diabetes, the hazard ratio for transitioning from State 2 to State 3 was 1.799 (95% CI 1.518&#x02013;2.131), indicating a 79.9% higher likelihood of developing severe symptoms. Furthermore, the hazard ratio for the transition from State 3 to State 4 is 1.899 (95% CI 1.023, 3.525), revealing that individuals with diabetes are 89.9% more likely to deteriorate to a critical state compared to those without diabetes. These findings underscore the influence of comorbidities such as hypertension and diabetes in exacerbating the clinical course of COVID-19, significantly increasing the risk of progression to more severe and critical states.
<table-wrap id="Tab6"><label>Table 6</label><caption><p>Transition intensities with hazard ratios for covariates diabetes and hypertension</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Transition</th><th align="left">Baseline transition rate</th><th align="left">Hypertension (HR)</th><th align="left">Diabetes (HR)</th></tr></thead><tbody><tr><td align="left">State 1&#x02013;State 1</td><td align="left"><p>&#x02009;&#x02212;&#x02009;0.166</p><p>(&#x02212;&#x02009;0.18,&#x02009;&#x02212;&#x02009;0.153)</p></td><td align="left"/><td align="left"/></tr><tr><td align="left">State 1&#x02013;State 2</td><td align="left"><p>0.166</p><p>(0.153,0.18)</p></td><td align="left"><p>1.142</p><p>(0.961,1.357)</p></td><td align="left"><p>0.98</p><p>(0.794,1.21)</p></td></tr><tr><td align="left">State 1&#x02013;State 5</td><td align="left"><p>1.66e<sup>&#x02212;05</sup></p><p>(4.124 e&#x02212;09,0.067)</p></td><td align="left"><p>0.664</p><p>(6.452e<sup>&#x02212;09</sup>,6.832e<sup>07</sup>)</p></td><td align="left"><p>0.803</p><p>(1.036e<sup>&#x02212;10</sup>,6.223e<sup>09</sup>)</p></td></tr><tr><td align="left">State 2&#x02013;State 1</td><td align="left"><p>0.046</p><p>(0.044,0.049)</p></td><td align="left"><p>1.229</p><p>(1.062,1.423)</p></td><td align="left"><p>1.162</p><p>(0.966,1.398)</p></td></tr><tr><td align="left">State 2&#x02013;State 2</td><td align="left"><p>&#x02009;&#x02212;&#x02009;0.086</p><p>(&#x02212;&#x02009;0.09,&#x02009;&#x02212;&#x02009;0.082)</p></td><td align="left"/><td align="left"/></tr><tr><td align="left">State 2&#x02013;State 3</td><td align="left"><p>0.04</p><p>(0.037,0.042)</p></td><td align="left"><p>1.676</p><p>(1.445,1.944)</p></td><td align="left"><p>1.799</p><p>(1.518,2.131)</p></td></tr><tr><td align="left">State 2&#x02013;State 5</td><td align="left"><p>3.234e<sup>&#x02212;05</sup></p><p>(1.921e<sup>&#x02212;06</sup>, 5.444e<sup>&#x02212;04</sup>)</p></td><td align="left"><p>0.227</p><p>(4.941e<sup>&#x02212;05</sup>,1.045e<sup>+03</sup></p></td><td align="left"><p>0.4431</p><p>(1.427e<sup>&#x02212;05</sup>,1.376e<sup>+04</sup>)</p></td></tr><tr><td align="left">State 3&#x02013;State 2</td><td align="left"><p>0.195</p><p>(0.18, 0.212)</p></td><td align="left"><p>1.038</p><p>(0.875,1.23)</p></td><td align="left"><p>0.9553</p><p>(0.783,1.165)</p></td></tr><tr><td align="left">State 3&#x02013;State 3</td><td align="left"><p>&#x02009;&#x02212;&#x02009;0.208</p><p>(&#x02212;&#x02009;0.225,&#x02009;&#x02212;&#x02009;0.192)</p></td><td align="left"/><td align="left"/></tr><tr><td align="left">State 3&#x02013;State 4</td><td align="left"><p>0.001</p><p>(0.008, 0.017)</p></td><td align="left"><p>1.6</p><p>(0.881,2.909)</p></td><td align="left">1.8989 (1.023,3.525)</td></tr><tr><td align="left">State 3&#x02013;State 5</td><td align="left"><p>7.829e<sup>&#x02212;05</sup></p><p>(4.422e<sup>&#x02212;07</sup>, 0.013)</p></td><td align="left"><p>2.132</p><p>(0.222,2.049e<sup>+01</sup>)</p></td><td align="left"><p>84.999</p><p>(1.882e<sup>&#x02212;01</sup>, 3.838e<sup>+04</sup>)</p></td></tr><tr><td align="left">State 4&#x02013;State 3</td><td align="left"><p>0.223</p><p>(0.143, 0.349)</p></td><td align="left"><p>0.722</p><p>(0.324,1.609)</p></td><td align="left"><p>1.717</p><p>(0.745,3.955)</p></td></tr><tr><td align="left">State 4&#x02013;State 4</td><td align="left"><p>&#x02009;&#x02212;&#x02009;0.227</p><p>(&#x02212;&#x02009;0.354,&#x02009;&#x02212;&#x02009;0.144)</p></td><td align="left"/><td align="left"/></tr><tr><td align="left">State 4&#x02013;State 5</td><td align="left"><p>2.865e<sup>&#x02212;03</sup></p><p>(2.396e<sup>&#x02212;05</sup>, 0.342)</p></td><td align="left"><p>10.4755</p><p>(1.224e<sup>&#x02212;02</sup>,8.968e<sup>+03</sup>)</p></td><td align="left"><p>0.26</p><p>(8.642e<sup>&#x02212;05</sup>, 7.839e<sup>+02</sup>)</p></td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par28">This study utilized continuous-time Markov multistate models to investigate the progression dynamics of COVID-19 among hospitalized patients. The analysis focused on patient transitions within the first 2&#x000a0;weeks of hospitalization and revealed that most patients remained in their initial health state, indicating a general stabilization during the early stages of hospitalization. Notably, patients classified in State 2 exhibited the highest frequency of stabilization compared to all other severity states. Furthermore, patients in higher severity states showed a tendency to improve to lower severity states rather than deteriorate. Specifically, the likelihood of improving from State 3 to State 2 was found to be greater than the likelihood of worsening to State 4. These results indicate a trend toward recovery rather than symptom aggravation among the patients in this cohort. This trend can be attributed to the Korean government's effective and rapid response during the early phase of the pandemic, which prioritized widespread screening to detect the virus before it progressed to high-risk stages of severity. In the South Korean healthcare system, patients diagnosed with COVID-19 were classified based on the severity of their symptoms and treated accordingly [<xref ref-type="bibr" rid="CR37">37</xref>]. Additionally, treatment strategies focused on identifying high-risk patients, particularly those over 60&#x000a0;years of age, individuals with diabetes, and those with weakened immune systems, prioritizing them for hospital care [<xref ref-type="bibr" rid="CR38">38</xref>]. The timely implementation of vaccination in South Korea likely further contributed to the increased recovery rates observed among COVID-19 patients [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. These coordinated strategies were pivotal in achieving the high recovery rates observed in the Korean population, including the cohort analyzed in this study.</p><p id="Par29">The incidence of hypertension and diabetes among infected patients was found to influence the aggravation of symptoms of COVID-19. Hypertension increases the likelihood of transitioning from moderate to severe disease states, while diabetes escalates the risk of aggravating from severe to critical conditions. Several mechanisms may contribute to the increased severity, including the upregulation of angiotensin-converting enzyme (ACE2), the receptor through which SARS-CoV-2 enters the host cell [<xref ref-type="bibr" rid="CR41">41</xref>]. Both hypertension and diabetes, particularly when treated with ACE inhibitors or angiotensin II receptor blockers (ARBs), are associated with elevated ACE2 expression, potentially facilitating enhanced viral entry and replication. Additionally, diabetes has been found to impair immune responses and promote a pro-inflammatory state, further exacerbating the severity of COVID-19 [<xref ref-type="bibr" rid="CR42">42</xref>]. These factors contribute to the heightened vulnerability of patients with diabetes and hypertension to rapid disease progression and severe outcomes, highlighting the critical need for tailored interventions and rigorous monitoring in these high-risk populations.</p><p id="Par30">This study has several limitations. First, our dataset includes only clinical and demographic information, lacking important details such as patients&#x02019; vaccination status and the specific SARS-Cov-2 strains involved. Consequently, we were unable to assess the potential impact of vaccination or the variations in disease progression due to different viral strains. Second, this study utilized data exclusively collected during the hospitalization of COVID-19 patients. Due to the unavailability of pre-admission records, the dataset does not include information on patients' health conditions before hospitalization, including the period between the onset of symptoms and hospital admission. This limitation restricts our ability to evaluate the onset and progression of COVID-19 symptoms, which may influence the severity of the disease at the time of admission. Additionally, the study did not capture the time elapsed between infection and hospital admission. As patients were admitted at varying time points following infection, this introduces variability in disease progression that could not be fully accounted for in the analysis. Additionally, the data were collected from one single hospital in South Korea, which may limit the generalizability of our findings to a broader, global population. Future studies should aim to incorporate more diverse datasets from multiple regions and healthcare systems to enable a more comprehensive analysis that accounts for vaccination status and the evolving nature of the pandemic. Additionally, while this study employed continuous-time Markov multistate models, future research could also explore discrete-time Markov multistate models, which are particularly effective when data is collected at regular intervals, such as daily or weekly assessments. Discrete-time models facilitate the analysis of transition probabilities over fixed periods, offering valuable insights into the timing and patterns of disease progression. By integrating both continuous and discrete-time modeling approaches, future studies can provide a more nuanced understanding of COVID-19 progression and recovery dynamics, ultimately contributing to the refinement of global treatment and management strategies.</p></sec><sec id="Sec17"><title>Conclusion</title><p id="Par31">This study employed continuous-time Markov multistate models to analyze the longitudinal progression and recovery dynamics of COVID-19 among hospitalized patients in a Korean cohort. The findings indicate that patients often stabilize in their initial health state during the early days of hospitalization, with a greater tendency for recovery than deterioration. Transition intensities show a high likelihood of mild symptoms worsening to moderate, yet recovery potential remains even in severe cases. The analysis highlights the importance of continuous monitoring and timely intervention, especially for patients in severe and critical states, while also demonstrating that comorbidities such as hypertension and diabetes significantly influence disease progression. Overall, this study underscores the need for proactive and individualized management strategies to effectively address the diverse progression patterns of COVID-19, particularly in high-risk patients, ultimately enhancing patient outcomes.</p></sec><sec id="Sec954" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="44342_2024_35_MOESM1_ESM.docx"><caption><p>Supplementary Table 1: Classification of COVID-19 Severity according to WHO.</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>TP designed and conceptualized the study. FARN performed data analysis and generated the tables and figures. FARN and TP interpreted the results. FARN drafted the manuscript. TP revised the manuscript. TP supervised the study. All authors contributed to the article and approved the submitted version.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research was supported by research grants from the Ministry of Science and Information &#x00026; Communication Technology, South Korea (No. 2021M3E5E3081425).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The dataset for this study is available on request to the corresponding author.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par32">Ethical compliance for this study involving human participants was ensured. The study protocol was approved by the Institutional Review Board of Seoul National University Boramae Medical Centre (IRB approval number 30&#x02013;2020-054).</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par33">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par34">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F</given-names></name><etal/></person-group><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><year>2020</year><volume>579</volume><issue>7798</issue><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2008-3</pub-id><pub-id pub-id-type="pmid">32015508</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Wu F, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265&#x02013;9.<pub-id pub-id-type="pmid">32015508</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Gorbalenya</surname><given-names>A</given-names></name><etal/></person-group><article-title>The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2</article-title><source>Nat Microbiol</source><year>2020</year><volume>5</volume><issue>4</issue><fpage>536</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0695-z</pub-id><pub-id pub-id-type="pmid">32123347</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Gorbalenya A, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536&#x02013;44.<pub-id pub-id-type="pmid">32123347</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R</given-names></name><etal/></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title><source>The lancet</source><year>2020</year><volume>395</volume><issue>10224</issue><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Lu R, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The lancet. 2020;395(10224):565&#x02013;74.</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Group, W.B. World Development Report 2022. Chapter 1. The economic impacts of the COVID-19 crisis [Website] 2022 [cited 2024 20 July 2024]; Available from: <ext-link ext-link-type="uri" xlink:href="https://www.worldbank.org/en/publication/wdr2022/brief/chapter-1-introduction-the-economic-impacts-of-the-covid-19-crisis">https://www.worldbank.org/en/publication/wdr2022/brief/chapter-1-introduction-the-economic-impacts-of-the-covid-19-crisis</ext-link>.</mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Naseer</surname><given-names>S</given-names></name><etal/></person-group><article-title>COVID-19 outbreak: impact on global economy</article-title><source>Front Public Health</source><year>2023</year><volume>10</volume><fpage>1009393</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2022.1009393</pub-id><pub-id pub-id-type="pmid">36793360</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Naseer S, et al. COVID-19 outbreak: impact on global economy. Front Public Health. 2023;10:1009393.<pub-id pub-id-type="pmid">36793360</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Dubey</surname><given-names>S</given-names></name><etal/></person-group><article-title>Psychosocial impact of COVID-19</article-title><source>Diabetes Metab Syndr</source><year>2020</year><volume>14</volume><issue>5</issue><fpage>779</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1016/j.dsx.2020.05.035</pub-id><pub-id pub-id-type="pmid">32526627</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Dubey S, et al. Psychosocial impact of COVID-19. Diabetes Metab Syndr. 2020;14(5):779&#x02013;88.<pub-id pub-id-type="pmid">32526627</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Kupcova</surname><given-names>I</given-names></name><etal/></person-group><article-title>Effects of the COVID-19 pandemic on mental health, anxiety, and depression</article-title><source>BMC psychology</source><year>2023</year><volume>11</volume><issue>1</issue><fpage>108</fpage><pub-id pub-id-type="doi">10.1186/s40359-023-01130-5</pub-id><pub-id pub-id-type="pmid">37041568</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Kupcova I, et al. Effects of the COVID-19 pandemic on mental health, anxiety, and depression. BMC psychology. 2023;11(1):108.<pub-id pub-id-type="pmid">37041568</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Leclerc QJ, et al. What settings have been linked to SARS-CoV-2 transmission clusters?. Wellcome Open Res. 2020;5.</mixed-citation></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>AG</given-names></name><name><surname>Lin</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name></person-group><article-title>Mechanisms of SARS-CoV-2 transmission and pathogenesis</article-title><source>Trends Immunol</source><year>2020</year><volume>41</volume><issue>12</issue><fpage>1100</fpage><lpage>1115</lpage><pub-id pub-id-type="doi">10.1016/j.it.2020.10.004</pub-id><pub-id pub-id-type="pmid">33132005</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 2020;41(12):1100&#x02013;15.<pub-id pub-id-type="pmid">33132005</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Cevik M, et al. Virology, transmission, and pathogenesis of SARS-CoV-2. bmj. 2020;371.</mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>H</given-names></name><etal/></person-group><article-title>The association between international and domestic air traffic and the coronavirus (COVID-19) outbreak</article-title><source>J Microbiol Immunol Infect</source><year>2020</year><volume>53</volume><issue>3</issue><fpage>467</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.jmii.2020.03.026</pub-id><pub-id pub-id-type="pmid">32299783</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Lau H, et al. The association between international and domestic air traffic and the coronavirus (COVID-19) outbreak. J Microbiol Immunol Infect. 2020;53(3):467&#x02013;72.<pub-id pub-id-type="pmid">32299783</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Eurosurveillance Editorial Team. Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern. Eurosurveillance. 2020;25(5):200131e.</mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Organization, W.H. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. 2020 11 March 2020 [cited 2024 25 July 2024]; Available from: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020">https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020</ext-link>.</mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Organization, W.H. WHO COVID-19 dashboard. 2024 August 1 [cited 2024 August 1]; Available from: <ext-link ext-link-type="uri" xlink:href="https://data.who.int/dashboards/covid19/cases?n=c">https://data.who.int/dashboards/covid19/cases?n=c</ext-link>.</mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Baj J, et al. COVID-19: specific and non-specific clinical manifestations and symptoms: the current state of knowledge. J Clin Med. 2020;9(6):1753.</mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">World Health Organization. Clinical management of COVID-19: interim guidance, 27 May 2020. World Health Organization; 2020. <ext-link ext-link-type="uri" xlink:href="https://iris.who.int/handle/10665/332196">https://iris.who.int/handle/10665/332196</ext-link>.</mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>NG</given-names></name><etal/></person-group><article-title>Age-dependent effects in the transmission and control of COVID-19 epidemics</article-title><source>Nat Med</source><year>2020</year><volume>26</volume><issue>8</issue><fpage>1205</fpage><lpage>1211</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0962-9</pub-id><pub-id pub-id-type="pmid">32546824</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Davies NG, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020;26(8):1205&#x02013;11.<pub-id pub-id-type="pmid">32546824</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W-J</given-names></name><etal/></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>18</issue><fpage>1708</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><pub-id pub-id-type="pmid">32109013</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Guan W-J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708&#x02013;20.<pub-id pub-id-type="pmid">32109013</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Wu, Z. and J.M. McGoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. jama. 2020;323(13):1239&#x02013;1242.</mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>AK</given-names></name><name><surname>Mishra</surname><given-names>S</given-names></name><name><surname>Gopalan</surname><given-names>SS</given-names></name></person-group><article-title>Predicting CoVID-19 community mortality risk using machine learning and development of an online prognostic tool</article-title><source>PeerJ</source><year>2020</year><volume>8</volume><fpage>e10083</fpage><pub-id pub-id-type="doi">10.7717/peerj.10083</pub-id><pub-id pub-id-type="pmid">33062451</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Das AK, Mishra S, Gopalan SS. Predicting CoVID-19 community mortality risk using machine learning and development of an online prognostic tool. PeerJ. 2020;8:e10083.<pub-id pub-id-type="pmid">33062451</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Saadatmand</surname><given-names>S</given-names></name><etal/></person-group><article-title>Using machine learning in prediction of ICU admission, mortality, and length of stay in the early stage of admission of COVID-19 patients</article-title><source>Ann Oper Res</source><year>2023</year><volume>328</volume><issue>1</issue><fpage>1043</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1007/s10479-022-04984-x</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Saadatmand S, et al. Using machine learning in prediction of ICU admission, mortality, and length of stay in the early stage of admission of COVID-19 patients. Ann Oper Res. 2023;328(1):1043&#x02013;71.</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A deep learning method for predicting the COVID-19 ICU patient outcome fusing X-rays, respiratory sounds, and ICU parameters</article-title><source>Expert Syst Appl</source><year>2024</year><volume>235</volume><fpage>121089</fpage><pub-id pub-id-type="doi">10.1016/j.eswa.2023.121089</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Wu Y, et al. A deep learning method for predicting the COVID-19 ICU patient outcome fusing X-rays, respiratory sounds, and ICU parameters. Expert Syst Appl. 2024;235:121089.</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>RK</given-names></name><name><surname>Pandey</surname><given-names>R</given-names></name><name><surname>Babu</surname><given-names>RN</given-names></name></person-group><article-title>COVIDScreen: explainable deep learning framework for differential diagnosis of COVID-19 using chest X-rays</article-title><source>Neural Comput Appl</source><year>2021</year><volume>33</volume><issue>14</issue><fpage>8871</fpage><lpage>8892</lpage><pub-id pub-id-type="doi">10.1007/s00521-020-05636-6</pub-id><pub-id pub-id-type="pmid">33437132</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Singh RK, Pandey R, Babu RN. COVIDScreen: explainable deep learning framework for differential diagnosis of COVID-19 using chest X-rays. Neural Comput Appl. 2021;33(14):8871&#x02013;92.<pub-id pub-id-type="pmid">33437132</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>T</given-names></name><etal/></person-group><article-title>COVID-19 severity detection using chest X-ray segmentation and deep learning</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>19846</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-70801-z</pub-id><pub-id pub-id-type="pmid">39191941</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Singh T, et al. COVID-19 severity detection using chest X-ray segmentation and deep learning. Sci Rep. 2024;14(1):19846.<pub-id pub-id-type="pmid">39191941</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>E</given-names></name><etal/></person-group><article-title>Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study</article-title><source>PLoS ONE</source><year>2021</year><volume>16</volume><issue>10</issue><fpage>e0258154</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0258154</pub-id><pub-id pub-id-type="pmid">34610047</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Ge E, et al. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study. PLoS ONE. 2021;16(10):e0258154.<pub-id pub-id-type="pmid">34610047</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>P</given-names></name><etal/></person-group><article-title>Impact of comorbidity on patients with COVID-19 in India: a nationwide analysis</article-title><source>Front Public Health</source><year>2023</year><volume>10</volume><fpage>1027312</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2022.1027312</pub-id><pub-id pub-id-type="pmid">36777781</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Singh P, et al. Impact of comorbidity on patients with COVID-19 in India: a nationwide analysis. Front Public Health. 2023;10:1027312.<pub-id pub-id-type="pmid">36777781</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Noh</surname><given-names>E</given-names></name><etal/></person-group><article-title>Inference and forecasting phase shift regime of COVID-19 sub-lineages with a Markov-switching model</article-title><source>Microbiology Spectrum</source><year>2023</year><volume>11</volume><issue>6</issue><fpage>e01669</fpage><lpage>e1723</lpage><pub-id pub-id-type="doi">10.1128/spectrum.01669-23</pub-id><pub-id pub-id-type="pmid">37811981</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Noh E, et al. Inference and forecasting phase shift regime of COVID-19 sub-lineages with a Markov-switching model. Microbiology Spectrum. 2023;11(6):e01669-e1723.<pub-id pub-id-type="pmid">37811981</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Mustafa</surname><given-names>S</given-names></name></person-group><article-title>A data-driven Markov process for infectious disease transmission</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><issue>8</issue><fpage>e0289897</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0289897</pub-id><pub-id pub-id-type="pmid">37561743</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Wang C, Mustafa S. A data-driven Markov process for infectious disease transmission. PLoS ONE. 2023;18(8):e0289897.<pub-id pub-id-type="pmid">37561743</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Hazard</surname><given-names>D</given-names></name><etal/></person-group><article-title>Joint analysis of duration of ventilation, length of intensive care, and mortality of COVID-19 patients: a multistate approach</article-title><source>BMC Med Res Methodol</source><year>2020</year><volume>20</volume><issue>1</issue><fpage>206</fpage><pub-id pub-id-type="doi">10.1186/s12874-020-01082-z</pub-id><pub-id pub-id-type="pmid">32781984</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Hazard D, et al. Joint analysis of duration of ventilation, length of intensive care, and mortality of COVID-19 patients: a multistate approach. BMC Med Res Methodol. 2020;20(1):206.<pub-id pub-id-type="pmid">32781984</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Zoughool</surname><given-names>M</given-names></name><etal/></person-group><article-title>Using a stochastic continuous-time Markov chain model to examine alternative timing and duration of the COVID-19 lockdown in Kuwait: what can be done now?</article-title><source>Archives of Public Health</source><year>2022</year><volume>80</volume><issue>1</issue><fpage>22</fpage><pub-id pub-id-type="doi">10.1186/s13690-021-00778-y</pub-id><pub-id pub-id-type="pmid">34998438</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Al-Zoughool M, et al. Using a stochastic continuous-time Markov chain model to examine alternative timing and duration of the COVID-19 lockdown in Kuwait: what can be done now? Archives of Public Health. 2022;80(1):22.<pub-id pub-id-type="pmid">34998438</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Mude W, et al. Racial disparities in COVID-19 pandemic cases, hospitalisations, and deaths: A systematic review and meta-analysis. J Glob Health. 2021;11.</mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Dergiades</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effectiveness of government policies in response to the first COVID-19 outbreak</article-title><source>PLOS Global Public Health</source><year>2022</year><volume>2</volume><issue>4</issue><fpage>e0000242</fpage><pub-id pub-id-type="doi">10.1371/journal.pgph.0000242</pub-id><pub-id pub-id-type="pmid">36962226</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Dergiades T, et al. Effectiveness of government policies in response to the first COVID-19 outbreak. PLOS Global Public Health. 2022;2(4):e0000242.<pub-id pub-id-type="pmid">36962226</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Escobedo-de la Pe&#x000f1;a, J., et al., Hypertension, diabetes and obesity, major risk factors for death in patients with COVID-19 in Mexico. Archives of medical research. 2021; 52(4):443&#x02013;449.</mixed-citation></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Albitar</surname><given-names>O</given-names></name><etal/></person-group><article-title>Risk factors for mortality among COVID-19 patients</article-title><source>Diabetes Res Clin Pract</source><year>2020</year><volume>166</volume><fpage>108293</fpage><pub-id pub-id-type="doi">10.1016/j.diabres.2020.108293</pub-id><pub-id pub-id-type="pmid">32623035</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Albitar O, et al. Risk factors for mortality among COVID-19 patients. Diabetes Res Clin Pract. 2020;166:108293.<pub-id pub-id-type="pmid">32623035</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Du P, et al. A systematic review and meta-analysis of risk factors associated with severity and death in COVID-19 patients. Canadian Journal of Infectious Diseases and Medical Microbiology. 2021;2021(1):6660930.</mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Jackson C. msm: Multi-state Markov and hidden Markov models in continuous time. R package version 0.8 1. 2008.</mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>You</surname><given-names>J</given-names></name></person-group><article-title>Lessons from South Korea&#x02019;s Covid-19 policy response</article-title><source>The American Review of Public Administration</source><year>2020</year><volume>50</volume><issue>6&#x02013;7</issue><fpage>801</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1177/0275074020943708</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">You J. Lessons from South Korea&#x02019;s Covid-19 policy response. The American Review of Public Administration. 2020;50(6&#x02013;7):801&#x02013;8.</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>J</given-names></name><etal/></person-group><article-title>National response to COVID-19 in the Republic of Korea and lessons learned for other countries</article-title><source>Health Systems &#x00026; Reform</source><year>2020</year><volume>6</volume><issue>1</issue><fpage>e1753464</fpage><pub-id pub-id-type="doi">10.1080/23288604.2020.1753464</pub-id><pub-id pub-id-type="pmid">32347772</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Oh J, et al. National response to COVID-19 in the Republic of Korea and lessons learned for other countries. Health Systems &#x00026; Reform. 2020;6(1):e1753464.<pub-id pub-id-type="pmid">32347772</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of national Covid-19 vaccination campaign</article-title><source>South Korea Vaccine</source><year>2022</year><volume>40</volume><issue>26</issue><fpage>3670</fpage><lpage>3675</lpage><pub-id pub-id-type="pmid">35570077</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Yi S, et al. Impact of national Covid-19 vaccination campaign. South Korea Vaccine. 2022;40(26):3670&#x02013;5.<pub-id pub-id-type="pmid">35570077</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>SL</given-names></name><name><surname>Oh</surname><given-names>J</given-names></name></person-group><article-title>COVID-19 vaccination program in South Korea: a long journey toward a new normal</article-title><source>Health policy and technology</source><year>2022</year><volume>11</volume><issue>2</issue><fpage>100601</fpage><pub-id pub-id-type="doi">10.1016/j.hlpt.2022.100601</pub-id><pub-id pub-id-type="pmid">35127400</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Kwon SL, Oh J. COVID-19 vaccination program in South Korea: a long journey toward a new normal. Health policy and technology. 2022;11(2):100601.<pub-id pub-id-type="pmid">35127400</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>L</given-names></name><name><surname>Karakiulakis</surname><given-names>G</given-names></name><name><surname>Roth</surname><given-names>M</given-names></name></person-group><article-title>Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?</article-title><source>Lancet Respir Med</source><year>2020</year><volume>8</volume><issue>4</issue><fpage>e21</fpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30116-8</pub-id><pub-id pub-id-type="pmid">32171062</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21.<pub-id pub-id-type="pmid">32171062</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Bornstein</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Practical recommendations for the management of diabetes in patients with COVID-19</article-title><source>Lancet Diabetses Endocrinol</source><year>2020</year><volume>8</volume><issue>6</issue><fpage>546</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(20)30152-2</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Bornstein SR, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetses Endocrinol. 2020;8(6):546&#x02013;50.</mixed-citation></citation-alternatives></ref></ref-list></back></article>